Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy (TAO)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT01076764
First received: February 25, 2010
Last updated: May 16, 2013
Last verified: May 2013
  Purpose

Primary Objective:

  • To demonstrate the superior efficacy (composite of all-cause death + Myocardial Infarction (MI)) of Otamixaban to Unfractionated Heparin (UFH) + Eptifibatide

Secondary Objectives:

  • To demonstrate the superior efficacy (composite of all-cause death + MI + any stroke) of Otamixaban as compared to UFH + Eptifibatide
  • To document the effect of Otamixaban on rehospitalization or prolongation of hospitalization due to a new episode of myocardial ischemia/myocardial infarction as compared to UFH + eptifibatide
  • To document the effect on mortality (all cause death) of Otamixaban as compared to UFH + eptifibatide
  • To document the safety of Otamixaban as compared to UFH + eptifibatide
  • To document the effect of Otamixaban on thrombotic procedural complications during the index Percutaneous Coronary Intervention (PCI) as compared to UFH + eptifibatide

Condition Intervention Phase
Acute Coronary Syndrome
Drug: Otamixaban (XRP0673)
Drug: Otamixaban matching placebo
Drug: Unfractionated Heparin
Drug: Unfractionated Heparin matching placebo
Drug: Eptifibatide
Drug: Eptifibatide matching placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Triple-dummy Trial to Compare the Efficacy of Otamixaban With Unfractionated Heparin + Eptifibatide, in Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction Scheduled to Undergo an Early Invasive Strategy

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Efficacy: Adjudicated double composite of all-cause of death and new myocardial infarction [ Time Frame: from randomization (day 1) to day 7 ] [ Designated as safety issue: No ]
  • Safety: Adjudicated Thrombolysis In Myocardial Infarction (TIMI) significant bleeding (composite of TIMI major and minor) [ Time Frame: from day 1 to day 7 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Adjudicated Triple efficacy composite of all-cause death, new myocardial infarction and any stroke [ Time Frame: from day 1 to day 7 ] [ Designated as safety issue: No ]
  • Rehospitalization or prolongation of hospitalization due to a new episode of myocardial ischemia/myocardial infarction [ Time Frame: from day 1 to day 30 ] [ Designated as safety issue: No ]
  • Adjudicated all-cause death [ Time Frame: from day 1 to day 30 ] [ Designated as safety issue: No ]
  • Adjudicated Procedural thrombotic complications during the index PCI [ Time Frame: during index PCI ] [ Designated as safety issue: No ]

Enrollment: 13220
Study Start Date: April 2010
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Otamixaban - Dose 1

From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:

  • Drug A: Otamixaban dose 1
  • Drug B: UFH matching placebo

From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:

  • Drug C: Eptifibatide matching placebo
Drug: Otamixaban (XRP0673)

Pharmaceutical form: Intravenous (IV) solution

Route of administration: IV bolus followed by continuous IV infusion

Drug: Unfractionated Heparin matching placebo

Pharmaceutical form: Intravenous (IV) solution

Route of administration: IV bolus followed by continuous IV infusion

Drug: Eptifibatide matching placebo

Pharmaceutical form: Intravenous (IV) solution

Route of administration: IV bolus followed by continuous IV infusion

Experimental: Otamixaban - Dose 2

From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:

  • Drug A: Otamixaban dose 2
  • Drug B: UFH matching placebo

From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:

  • Drug C: Eptifibatide matching placebo
Drug: Otamixaban (XRP0673)

Pharmaceutical form: Intravenous (IV) solution

Route of administration: IV bolus followed by continuous IV infusion

Drug: Unfractionated Heparin matching placebo

Pharmaceutical form: Intravenous (IV) solution

Route of administration: IV bolus followed by continuous IV infusion

Drug: Eptifibatide matching placebo

Pharmaceutical form: Intravenous (IV) solution

Route of administration: IV bolus followed by continuous IV infusion

Active Comparator: UFH + Eptifibatide

From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:

  • Drug A: Otamixaban matching placebo
  • Drug B: UFH

From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:

  • Drug C: Eptifibatide
Drug: Otamixaban matching placebo

Pharmaceutical form: Intravenous (IV) solution

Route of administration: IV bolus followed by continuous IV infusion

Drug: Unfractionated Heparin

Pharmaceutical form: Intravenous (IV) solution

Route of administration: IV bolus followed by continuous IV infusion

Drug: Eptifibatide

Pharmaceutical form: Intravenous (IV) solution

Route of administration: IV bolus followed by continuous IV infusion


Detailed Description:

Up to the interim analysis, patients are randomized to one of the Otamixaban arms or the control arm (UFH + Eptifibatide). Then after interim analysis, patients will be randomized to the continued Otamixaban arm (per Data Monitoring Committee (DMC) decision based on interim analysis results) or the control arm (UFH + Eptifibatide). Except the DMC, all participants will remain blinded to this decision until the end of study.

The total duration of the study period per subject will range between 30 days and 180 days. Study end date being the Day 30 visit of the last randomized patient, follow up will be until Day 180 or study end date whichever comes first.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

Patient with non ST-segment elevation Acute Coronary Syndrome with:

  1. Ischemic symptoms (chest pain or equivalent) at rest ≥ 10 minutes within 24 hours of randomization,

    AND

  2. One of the two following criteria:

    • New ST-segment depression ≥ 0.1 mV (≥1 mm), or transient (< 30 minutes) ST-segment elevation ≥ 0.1 mV (≥ 1 mm) in at least 2 contiguous leads on the electrocardiogram,
    • Elevation of cardiac biomarkers within 24 hours of randomization, defined as elevated troponin T, troponin I, or CK-MB level above upper limit of normal,

    AND

  3. Planned to have a coronary angiography (followed, when indicated, by PCI) as early as possible (after at least 2 hours of treatment with study drug) and within 36 hours (at the latest on Day 3, if justified),

    AND

  4. Informed consent obtained in writing.

Exclusion criteria:

  • Revascularization procedure already performed for the qualifying event Acute ST-segment elevation MI.
  • Patient having received curative dose of anticoagulant treatment (including UFH, LMWH, or bivalirudin) for more than 24 hours prior to randomization or who have been treated by abciximab.
  • Inability to discontinue current anticoagulation in order to transition to Investigational Products according to the specified transition timing.
  • Patient who can not be treated by aspirin and clopidogrel (or any other oral antiplatelet agent) according to their local labeling.
  • Patient who cannot be treated with eptifibatide according to the national labeling (when available). In countries where eptifibatide is not approved the reference label to be considered is either the European labeling or the US labeling
  • Patient who cannot be treated with unfractionated heparin according to the national labeling.
  • Allergy to otamixaban.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01076764

  Hide Study Locations
Locations
United States, Alabama
Investigational Site Number 840015
Huntsville, Alabama, United States, 35801
United States, Arizona
Investigational Site Number 840703
Phoenix, Arizona, United States, 85054
Investigational Site Number 840569
Phoenix, Arizona, United States, 85008
United States, California
Investigational Site Number 840101
Anaheim, California, United States, 92801
Investigational Site Number 840151
Anaheim, California, United States, 92801
Investigational Site Number 840213
Beverley Hills, California, United States, 90211
Investigational Site Number 840572
Huntington Beach, California, United States, 92648
Investigational Site Number 840201
Long Beach, California, United States, 90806
Investigational Site Number 840557
Los Angeles, California, United States, 90024
Investigational Site Number 840071
Los Angeles, California, United States, 90024
Investigational Site Number 840903
Northridge, California, United States, 91328
Investigational Site Number 840065
San Francisco, California, United States, 94143
Investigational Site Number 840561
Santa Rosa, California, United States, 95405
United States, Colorado
Investigational Site Number 840721
Littleton, Colorado, United States, 80120
United States, Connecticut
Investigational Site Number 840551
Bridgeport, Connecticut, United States, 06606
Investigational Site Number 840166
New Haven, Connecticut, United States, 06511
United States, District of Columbia
Investigational Site Number 840520
Washington, District of Columbia, United States, 20010
United States, Florida
Investigational Site Number 840185
Fort Lauderdale, Florida, United States, 33322
Investigational Site Number 840028
Jacksonville, Florida, United States, 32204
Investigational Site Number 840047
Lake Mary, Florida, United States, 32746
Investigational Site Number 840500
Melbourne, Florida, United States, 32901
Investigational Site Number 840706
Miami, Florida, United States, 33133
Investigational Site Number 840146
Ocala, Florida, United States, 34471
Investigational Site Number 840009
Ocala, Florida, United States, 34471
Investigational Site Number 840577
Orlando, Florida, United States, 32803
Investigational Site Number 840021
Sarasota, Florida, United States, 34239
Investigational Site Number 840902
St. Petersburg, Florida, United States, 33701
Investigational Site Number 840508
Tampa, Florida, United States, 33613
United States, Georgia
Investigational Site Number 840719
Gainesville, Georgia, United States, 30501
United States, Idaho
Investigational Site Number 840532
Boise, Idaho, United States, 83712
United States, Illinois
Investigational Site Number 840105
Aurora, Illinois, United States, 60506
Investigational Site Number 840205
Chicago, Illinois, United States, 60637
Investigational Site Number 840190
Chicago, Illinois, United States, 60612
Investigational Site Number 840521
Harvey, Illinois, United States, 60426
Investigational Site Number 840148
Joliet, Illinois, United States, 60435
United States, Indiana
Investigational Site Number 840042
Hammond, Indiana, United States, 46320
Investigational Site Number 840554
Indianapolis, Indiana, United States, 46202
Investigational Site Number 840560
Muncie, Indiana, United States, 47303-3400
United States, Iowa
Investigational Site Number 840904
Ames, Iowa, United States, 50010
Investigational Site Number 840058
West Des Moines, Iowa, United States, 50266
United States, Kansas
Investigational Site Number 840912
Overland, Kansas, United States, 66209
United States, Kentucky
Investigational Site Number 840568
Louisville, Kentucky, United States, 40207
United States, Louisiana
Investigational Site Number 840534
Alexandria, Louisiana, United States, 71301
Investigational Site Number 840564
Lake Charles, Louisiana, United States, 70601
Investigational Site Number 840533
New Orleans, Louisiana, United States, 70112
United States, Michigan
Investigational Site Number 840517
Dearborn, Michigan, United States, 48123
Investigational Site Number 840544
Kalamazoo, Michigan, United States, 49007
Investigational Site Number 840531
Saginaw, Michigan, United States, 48602
United States, Minnesota
Investigational Site Number 840525
Minneapolis, Minnesota, United States, 55404
Investigational Site Number 840510
Minneapolis, Minnesota, United States, 55433
United States, Mississippi
Investigational Site Number 840527
Tupelo, Mississippi, United States, 38801
United States, Missouri
Investigational Site Number 840208
Bridgeton, Missouri, United States, 63044
Investigational Site Number 840209
Independence, Missouri, United States, 64057
Investigational Site Number 840056
Kansas City, Missouri, United States, 64128
Investigational Site Number 840138
Kansas City, Missouri, United States, 64114
Investigational Site Number 840194
Kansas City, Missouri, United States, 64108
Investigational Site Number 840580
St Louis, Missouri, United States, 63128
Investigational Site Number 840530
St Louis, Missouri, United States, 63128
Investigational Site Number 840210
St. Louis, Missouri, United States, 63128
Investigational Site Number 840052
St. Louis, Missouri, United States, 63131
United States, Montana
Investigational Site Number 840529
Kalispell, Montana, United States, 59901
United States, Nebraska
Investigational Site Number 840059
Omaha, Nebraska, United States, 68122
Investigational Site Number 840079
Omaha, Nebraska, United States, 68131
Investigational Site Number 840727
Omaha, Nebraska, United States, 68122
United States, Nevada
Investigational Site Number 840157
Reno, Nevada, United States, 89502
United States, New York
Investigational Site Number 840518
Brooklyn, New York, United States, 11215
Investigational Site Number 840539
New York, New York, United States, 10021
United States, North Carolina
Investigational Site Number 840585
Charlotte, North Carolina, United States, 28204
Investigational Site Number 840515
Greenville, North Carolina, United States, 27834
Investigational Site Number 840566
Raleigh, North Carolina, United States, 27610
Investigational Site Number 840908
Winston Salem, North Carolina, United States, 27157-1071
United States, North Dakota
Investigational Site Number 840136
Minot, North Dakota, United States, 58701
United States, Ohio
Investigational Site Number 840082
Toledo, Ohio, United States, 43608
United States, Oklahoma
Investigational Site Number 840025
Midwest City, Oklahoma, United States, 73110
Investigational Site Number 840049
Oklahoma City, Oklahoma, United States, 73112
Investigational Site Number 840905
Oklahoma City, Oklahoma, United States, 73112
Investigational Site Number 840193
Oklahoma City, Oklahoma, United States, 73135
Investigational Site Number 840901
Tulsa, Oklahoma, United States, 74104
United States, Oregon
Investigational Site Number 840206
Eugene, Oregon, United States, 97401
United States, Pennsylvania
Investigational Site Number 840540
Chambersburg, Pennsylvania, United States, 17201
Investigational Site Number 840519
Doylestown, Pennsylvania, United States, 18901
Investigational Site Number 840003
Erie, Pennsylvania, United States, 16502-4604
Investigational Site Number 840098
Harrisburg, Pennsylvania, United States, 17110
Investigational Site Number 840573
Philadelphia, Pennsylvania, United States, 19104
Investigational Site Number 840911
Pittsburgh, Pennsylvania, United States, 15240
Investigational Site Number 840075
Pittsburgh, Pennsylvania, United States, 15224
Investigational Site Number 840211
Washington, Pennsylvania, United States, 15301
United States, Tennessee
Investigational Site Number 840072
Oak Ridge, Tennessee, United States, 37830
United States, Texas
Investigational Site Number 840023
Amarillo, Texas, United States, 79106
Investigational Site Number 840203
Austin, Texas, United States, 78745
Investigational Site Number 840574
Austin, Texas, United States, 78758
Investigational Site Number 840578
Dallas, Texas, United States
Investigational Site Number 840060
Dallas, Texas, United States, 75216
Investigational Site Number 840715
Fort Worth, Texas, United States, 76104
Investigational Site Number 840090
Houston, Texas, United States, 77030
Investigational Site Number 840586
Houston, Texas, United States, 77096
Investigational Site Number 840559
Houston, Texas, United States, 77096
Investigational Site Number 840207
Houston, Texas, United States, 77030
Investigational Site Number 840087
Tyler, Texas, United States, 75701
Investigational Site Number 840910
Victoria, Texas, United States, 77901
Investigational Site Number 840555
Wichita Falls, Texas, United States, 76310
United States, Virginia
Investigational Site Number 840553
Richmond, Virginia, United States, 23249
Investigational Site Number 840188
Richmond, Virginia, United States, 23298
Investigational Site Number 840165
Salem, Virginia, United States, 24153
Investigational Site Number 840565
Winchester, Virginia, United States, 22601
United States, Washington
Investigational Site Number 840121
Tacoma, Washington, United States, 98405
United States, Wisconsin
Investigational Site Number 840513
Manitowoc, Wisconsin, United States, 54220
Argentina
Investigational Site Number 032048
Adrogue, Argentina, B1846DSK
Investigational Site Number 032013
Avellaneda, Argentina, 1870
Investigational Site Number 032003
Buenos Aires, Argentina, C1181ACH
Investigational Site Number 032032
Buenos Aires, Argentina, C1425FSD
Investigational Site Number 032046
Buenos Aires, Argentina, 1118
Investigational Site Number 032043
Buenos Aires, Argentina, C1118AAE
Investigational Site Number 032014
Caba, Argentina, B7400XAC
Investigational Site Number 032007
Capital Federal, Argentina, 1181
Investigational Site Number 032039
Capital Federal, Argentina, C1093AAS
Investigational Site Number 032045
Capital Federal, Argentina
Investigational Site Number 032029
Ciudad Autonoma De Bs.As, Argentina, 1428
Investigational Site Number 032036
Ciudad De Buenos Aires, Argentina, C1426BOR
Investigational Site Number 032044
Cordoba, Argentina, X5004BCL
Investigational Site Number 032010
Cordoba, Argentina, X5119XAA
Investigational Site Number 032001
Corrientes, Argentina, 3400
Investigational Site Number 032035
Florencio Varela, Argentina, B1888AAE
Investigational Site Number 032027
La Plata, Argentina
Investigational Site Number 032018
La Plata, Argentina, (B1900AXI)
Investigational Site Number 032020
Mendoza, Argentina, 5500
Investigational Site Number 032033
Olivos, Argentina, 1638
Investigational Site Number 032022
Pilar, Argentina, 1629
Investigational Site Number 032002
Resistencia, Argentina
Investigational Site Number 032023
Resistencia, Argentina, 3500
Investigational Site Number 032040
Rosario, Argentina, 2000
Investigational Site Number 032028
Rosario, Argentina, 2000
Investigational Site Number 032005
Rosario, Argentina, 2000
Investigational Site Number 032004
Rosario, Argentina, 2000
Investigational Site Number 032021
Rosario, Argentina, 2000
Investigational Site Number 032025
San Luis, Argentina, 5700
Investigational Site Number 032024
San Martin, Argentina, 1650
Investigational Site Number 032008
San Miguel De Tucuman, Argentina, T4000NIL
Investigational Site Number 032041
Santa Fe, Argentina, 3000
Investigational Site Number 032006
Santa Fe, Argentina, S3000FWO
Australia
Investigational Site Number 036008
Adelaide, Australia, 5000
Investigational Site Number 036004
Ballarat, Australia, 3353
Investigational Site Number 036010
Concord, Australia, 2137
Investigational Site Number 036001
Herston, Australia, 4029
Investigational Site Number 036913
Hobart, Australia, 7001
Investigational Site Number 036011
Liverpool, Australia, 2170
Investigational Site Number 036003
Prahran, Australia, 3004
Austria
Investigational Site Number 040001
Wien, Austria, 1160
Investigational Site Number 040002
Wien, Austria, 1090
Belarus
Investigational Site Number 112004
Gomel, Belarus, 246012
Investigational Site Number 112002
Minsk, Belarus, 220016
Investigational Site Number 112001
Minsk, Belarus, 220036
Investigational Site Number 112003
Minsk, Belarus, 220013
Belgium
Investigational Site Number 056001
Bonheiden, Belgium, 2820
Investigational Site Number 056007
Brugge, Belgium, 8000
Investigational Site Number 056003
Brussels, Belgium, 1020
Investigational Site Number 056006
Haine-Saint-Paul, Belgium, 7100
Investigational Site Number 056008
Leuven, Belgium, 3000
Brazil
Investigational Site Number 076025
Campinas, Brazil, 13015-001
Investigational Site Number 076011
Fortaleza, Brazil, 60864190
Investigational Site Number 076015
Marilia, Brazil, 17515-460
Investigational Site Number 076016
Maringa, Brazil, 87015-290
Investigational Site Number 076013
Passo Fundo, Brazil, 99010-080
Investigational Site Number 076001
Porto Alegre, Brazil, 90610-000
Investigational Site Number 076009
Porto Alegre, Brazil, 90035-001
Investigational Site Number 076004
Porto Alegre, Brazil, 91350-250
Investigational Site Number 076022
Porto Alegre, Brazil, 90620-001
Investigational Site Number 076030
Recife, Brazil, 52051-380
Investigational Site Number 076023
Recife, Brazil, 50100-060
Investigational Site Number 076027
Rio De Janeiro, Brazil, 20221903
Investigational Site Number 076029
Salvador, Brazil, 41148-900
Investigational Site Number 076002
Sao Jose Do Rio Preto, Brazil, 15090-000
Investigational Site Number 076014
Sao Jose Do Rio Preto, Brazil, 15015-210
Investigational Site Number 076012
Sao Paulo, Brazil, 01323-001
Investigational Site Number 076007
Sao Paulo, Brazil, 05403-000
Investigational Site Number 076020
Sao Paulo, Brazil, 04012-180
Investigational Site Number 076008
Uberlandia, Brazil, 38400-368
Investigational Site Number 076024
Votuporanga, Brazil, 15500-003
Bulgaria
Investigational Site Number 100511
Blagoevgrad, Bulgaria, 2700
Investigational Site Number 100508
Kazanlak, Bulgaria, 6100
Investigational Site Number 100512
Pazardjik, Bulgaria, 4400
Investigational Site Number 100505
Pleven, Bulgaria, 5800
Investigational Site Number 100509
Ruse, Bulgaria
Investigational Site Number 100510
Sandanski, Bulgaria, 2800
Investigational Site Number 100501
Sofia, Bulgaria, 1202
Investigational Site Number 100502
Sofia, Bulgaria, 1407
Investigational Site Number 100503
Sofia, Bulgaria, 1431
Investigational Site Number 100507
Varna, Bulgaria, 9000
Investigational Site Number 100504
Veliko Tarnovo, Bulgaria, 5000
Investigational Site Number 100506
Yambol, Bulgaria, 8600
Canada
Investigational Site Number 124005
Gatineau, Canada, J8Y 1W7
Investigational Site Number 124006
Hamilton, Canada, L8L 2X2
Investigational Site Number 124004
Montreal, Canada, H2W 1T8
Investigational Site Number 124001
Quebec, Canada, G1V 4G5
Investigational Site Number 124007
Sherbrooke, Canada, J1H 5N4
Investigational Site Number 124009
St. John, Canada, E2L 4L2
Investigational Site Number 124002
Toronto, Canada, M5B 1W8
Chile
Investigational Site Number 152003
Antofagasta, Chile
Investigational Site Number 152906
Concepcion, Chile, 4070038
Investigational Site Number 152005
Iquique, Chile
Investigational Site Number 152004
Santiago, Chile, 751-0009
Investigational Site Number 152901
Santiago, Chile, 8380456
Investigational Site Number 152012
Santiago, Chile
Investigational Site Number 152001
Santiago, Chile, 756-0171
Investigational Site Number 152903
Santiago, Chile, 890-0085
Investigational Site Number 152902
Santiago, Chile, 820-7257
Investigational Site Number 152010
Santiago, Chile
Investigational Site Number 152011
Talcahuano, Chile, 427-0918
Investigational Site Number 152908
Temuco, Chile
Investigational Site Number 152913
Temuco, Chile
Investigational Site Number 152016
Valdivia, Chile
Investigational Site Number 152912
Valparaíso, Chile, 234-0207
Investigational Site Number 152907
Vina Del Mar, Chile
Investigational Site Number 152910
Viña Del Mar, Chile
Colombia
Investigational Site Number 170016
Barranquilla, Colombia
Investigational Site Number 170009
Bogota, Colombia
Investigational Site Number 170011
Bogotá, Colombia
Investigational Site Number 170002
Bucaramanga, Colombia
Investigational Site Number 170012
Cali, Colombia
Investigational Site Number 170001
Medellin, Colombia
Investigational Site Number 170003
Medellin, Colombia
Investigational Site Number 170017
Medellin, Colombia
Croatia
Investigational Site Number 191502
Slavonski Brod, Croatia, 35000
Investigational Site Number 191503
Zagreb, Croatia, 10000
Investigational Site Number 191505
Zagreb, Croatia, 10000
Investigational Site Number 191506
Zagreb, Croatia, 10000
Czech Republic
Investigational Site Number 203005
Brno, Czech Republic, 62500
Investigational Site Number 203903
Hradec Kralove, Czech Republic, 50005
Investigational Site Number 203902
Liberec, Czech Republic, 46063
Investigational Site Number 203009
Olomouc, Czech Republic, 77520
Investigational Site Number 203010
Ostrava - Poruba, Czech Republic, 70852
Investigational Site Number 203001
Praha 10, Czech Republic, 10034
Investigational Site Number 203901
Praha 2, Czech Republic, 12808
Investigational Site Number 203007
Praha 5, Czech Republic, 15006
Investigational Site Number 203003
Praha 5, Czech Republic, 15030
Investigational Site Number 203002
Usti Nad Labem, Czech Republic, 40113
Investigational Site Number 203006
Zlin, Czech Republic, 76275
Egypt
Investigational Site Number 818504
Cairo, Egypt, 11451
Investigational Site Number 818502
Cairo, Egypt
Investigational Site Number 818501
Cairo, Egypt, 11566
Investigational Site Number 818503
Giza, Egypt
Estonia
Investigational Site Number 233901
Tallinn, Estonia, 13419
Investigational Site Number 233001
Tallinn, Estonia, 10138
France
Investigational Site Number 250016
Avignon Cedex 2, France, 84082
Investigational Site Number 250010
Bayonne, France, 64100
Investigational Site Number 250002
Belfort Cedex, France, 90016
Investigational Site Number 250001
Besancon, France, 25030
Investigational Site Number 250006
Creteil, France, 94010
Investigational Site Number 250003
Dijon Cedex, France, 21034
Investigational Site Number 250013
Le Chesnay Cedex, France, 78187
Investigational Site Number 250012
Montfermeil, France, 93370
Investigational Site Number 250015
Mulhouse, France, 68070
Investigational Site Number 250005
Mulhouse, France, 68067
Investigational Site Number 250009
Paris, France, 75018
Investigational Site Number 250011
Pau, France, 64046
Investigational Site Number 250007
Rouen, France, 76031
Investigational Site Number 250014
Strasbourg, France, 67091
Investigational Site Number 250008
Toulouse Cedex 9, France, 31059
Germany
Investigational Site Number 276004
Berlin, Germany, 13347
Investigational Site Number 276022
Berlin, Germany, 12559
Investigational Site Number 276024
Berlin, Germany, 13353
Investigational Site Number 276023
Bonn, Germany, 53115
Investigational Site Number 276006
Frankfurt Am Main, Germany, 65929
Investigational Site Number 276901
Freiburg, Germany, 79106
Investigational Site Number 276902
Hamburg, Germany, 22527
Investigational Site Number 276003
Hamburg, Germany, 22041
Investigational Site Number 276009
Heidelberg, Germany, 69120
Investigational Site Number 276904
Heidenheim, Germany, 89522
Investigational Site Number 276002
Kassel, Germany, 34121
Investigational Site Number 276013
Langen, Germany, 63225
Investigational Site Number 276001
Mainz, Germany, 55131
Investigational Site Number 276905
Mönchengladbach, Germany, 41063
Investigational Site Number 276005
München, Germany, 81377
Investigational Site Number 276018
Rostock, Germany, 18057
Greece
Investigational Site Number 300009
Alexandroupolis, Greece, 68100
Investigational Site Number 300001
Athens, Greece, 11527
Investigational Site Number 300004
Athens, Greece, 10676
Investigational Site Number 300011
Athens, Greece, 11528
Investigational Site Number 300007
Chios, Greece, 82100
Investigational Site Number 300008
Larissa, Greece, 41110
Investigational Site Number 300003
Melissia, Greece, 151 27
Investigational Site Number 300005
N. Ionia, Greece, 14233
Investigational Site Number 300002
Patras, Greece, 26500
Investigational Site Number 300006
Thessaloniki, Greece, 57010
Investigational Site Number 300010
Thessaloniki, Greece, 546 36
Hong Kong
Investigational Site Number 344001
Chai Wan, Hong Kong
Hungary
Investigational Site Number 348003
Budapest, Hungary, 1027
Investigational Site Number 348004
Budapest, Hungary, 1134
Investigational Site Number 348008
Budapest, Hungary, 1096
Investigational Site Number 348002
Budapest, Hungary, 1122
Investigational Site Number 348009
Szeged, Hungary, 6720
Investigational Site Number 348007
Szekesfehervar, Hungary, 8000
Investigational Site Number 348001
Szolnok, Hungary, 5000
Investigational Site Number 348005
Szombathely, Hungary, 9700
Investigational Site Number 348006
Zalaegerszeg, Hungary, 8900
India
Investigational Site Number 356004
Ahmedabad, India, 380054
Investigational Site Number 356007
Ahmedabad, India, 380060
Investigational Site Number 356019
Ahmedabad, India, 380014
Investigational Site Number 356012
Allahabad, India, 211003
Investigational Site Number 356008
Bangalore, India, 560054
Investigational Site Number 356020
Chandigarh, India, 160062
Investigational Site Number 356027
Gurgaon, India
Investigational Site Number 356029
Gurgaon, India, 122001
Investigational Site Number 356046
Hyderabad, India, 500055
Investigational Site Number 356040
Hyderabad, India, 500001
Investigational Site Number 356014
Jaipur, India
Investigational Site Number 356003
Karamsad, India, 388325
Investigational Site Number 356037
Kochi, India, 682018
Investigational Site Number 356034
Kolkata, India, 700027
Investigational Site Number 356039
Madurai, India, 625107
Investigational Site Number 356018
Mangalore, India
Investigational Site Number 356021
Mumbai, India, 400050
Investigational Site Number 356032
Mumbai, India
Investigational Site Number 356031
Mumbai, India
Investigational Site Number 356016
Mumbai, India
Investigational Site Number 356011
Mysore, India, 570020
Investigational Site Number 356022
Nagpur, India, 440012
Investigational Site Number 356023
Nagpur, India
Investigational Site Number 356035
Nagpur, India, 440012
Investigational Site Number 356036
Nashik, India, 422005
Investigational Site Number 356001
New Delhi, India, 110060
Investigational Site Number 356026
New Delhi, India
Investigational Site Number 356025
New Delhi, India, 110 070.
Investigational Site Number 356033
Pune, India, 411004
Investigational Site Number 356010
Pune, India, 411004
Investigational Site Number 356024
Secunderabad, India, 500 003
Investigational Site Number 356002
Varanasi, India, 221010
Investigational Site Number 356044
Vijaywada, India, 520002
Indonesia
Investigational Site Number 360505
Bandung, Indonesia, 40161
Investigational Site Number 360501
Depok, Indonesia, 16514
Investigational Site Number 360506
Jakarta, Indonesia, 10430
Investigational Site Number 360503
Jakarta, Indonesia, 11420
Investigational Site Number 360502
Jakarta, Indonesia, 12950
Israel
Investigational Site Number 376005
Afula, Israel, 18101
Investigational Site Number 376003
Ashkelon, Israel, 78278
Investigational Site Number 376011
Hadera, Israel, 38100
Investigational Site Number 376009
Haifa, Israel, 31096
Investigational Site Number 376004
Haifa, Israel, 31048
Investigational Site Number 376010
Holon, Israel, 58100
Investigational Site Number 376002
Jerusalem, Israel, 91031
Investigational Site Number 376013
Jerusalem, Israel, 91120
Investigational Site Number 376007
Safed, Israel, 13100
Investigational Site Number 376008
Tel Aviv, Israel, 64239
Investigational Site Number 376001
Tel Hashomer, Israel, 52621
Investigational Site Number 376012
Tzrifin, Israel, 70300
Italy
Investigational Site Number 380902
Bergamo, Italy, 24127
Investigational Site Number 380918
Bologna, Italy, 40138
Investigational Site Number 380928
Brescia, Italy, 25124
Investigational Site Number 380904
Brescia, Italy, 25123
Investigational Site Number 380929
Castellanza, Italy, 21053
Investigational Site Number 380930
Catania, Italy, 95123
Investigational Site Number 380912
Catania, Italy, 95124
Investigational Site Number 380932
Cittadella, Italy, 35013
Investigational Site Number 380926
Conegliano, Italy, 31015
Investigational Site Number 380909
Empoli, Italy, 50053
Investigational Site Number 380924
Forlì, Italy, 47100
Investigational Site Number 380908
Livorno, Italy, 57123
Investigational Site Number 380923
Massa, Italy, 54100
Investigational Site Number 380935
Massa, Italy, 54100
Investigational Site Number 380933
Messina, Italy, 98100
Investigational Site Number 380910
Milano, Italy, 20138
Investigational Site Number 380905
Modena, Italy, 41041
Investigational Site Number 380936
Napoli, Italy, 88100
Investigational Site Number 380901
Perugia, Italy, 06132
Investigational Site Number 380907
Pescara, Italy, 65100
Investigational Site Number 380919
Pordenone, Italy, 33170
Investigational Site Number 380916
Reggio Emilia, Italy, 42100
Investigational Site Number 380917
Roma, Italy, 00189
Investigational Site Number 380931
Roma, Italy, 00168
Investigational Site Number 380927
Rovigo, Italy, 45100
Investigational Site Number 380921
Rozzano, Italy, 20089
Investigational Site Number 380914
Seriate, Italy, 24068
Investigational Site Number 380925
Treviso, Italy, 31100
Jordan
Investigational Site Number 400501
Amman, Jordan, 520248
Investigational Site Number 400502
Irbid, Jordan, 360001
Korea, Republic of
Investigational Site Number 410006
Busan, Korea, Republic of, 614-735
Investigational Site Number 410005
Busan, Korea, Republic of, 602-715
Investigational Site Number 410014
Daegu, Korea, Republic of, 705-717
Investigational Site Number 410002
Daegu, Korea, Republic of, 700-712
Investigational Site Number 410017
Daejeon, Korea, Republic of
Investigational Site Number 410004
Goyang, Korea, Republic of, 410-773
Investigational Site Number 410018
Guri, Korea, Republic of, 471-020
Investigational Site Number 410016
Gwangju, Korea, Republic of, 501-757
Investigational Site Number 410007
Seongnam, Korea, Republic of, 463-707
Investigational Site Number 410011
Seoul, Korea, Republic of, 130-709
Investigational Site Number 410003
Seoul, Korea, Republic of, 152-703
Investigational Site Number 410012
Seoul, Korea, Republic of, 120-752
Investigational Site Number 410001
Seoul, Korea, Republic of, 134-727
Investigational Site Number 410008
Seoul, Korea, Republic of, 110-744
Investigational Site Number 410010
Seoul, Korea, Republic of, 138-736
Investigational Site Number 410009
Seoul, Korea, Republic of, 137-701
Investigational Site Number 410013
Suwon, Korea, Republic of, 443-721
Investigational Site Number 410015
Wonju, Korea, Republic of, 220-701
Latvia
Investigational Site Number 428004
Daugavpils, Latvia, LV-5417
Investigational Site Number 428002
Liepaja, Latvia, LV-3414
Investigational Site Number 428003
Riga, Latvia, LV-1038
Investigational Site Number 428001
Riga, Latvia, LV-1002
Lebanon
Investigational Site Number 422502
Beirut, Lebanon, Beirut
Investigational Site Number 422505
Beirut, Lebanon
Lithuania
Investigational Site Number 440003
Kaunas, Lithuania, LT-50009
Investigational Site Number 440001
Siauliai, Lithuania, LT-76231
Investigational Site Number 440904
Vilnius, Lithuania, LT-08661
Macedonia, The Former Yugoslav Republic of
Investigational Site Number 807501
Skopje, Macedonia, The Former Yugoslav Republic of, 1109
Malaysia
Investigational Site Number 458001
Kuching, Malaysia, 93586
Mexico
Investigational Site Number 484907
Aguascalientes, Mexico, 20230
Investigational Site Number 484009
Aguascalientes, Mexico, 20230
Investigational Site Number 484902
Guadalajara, Mexico, 44100
Investigational Site Number 484901
Guadalajara, Mexico, CP 64630
Investigational Site Number 484015
Guadalajara, Mexico, 44670
Investigational Site Number 484019
Merida, Mexico, 97000
Investigational Site Number 484003
Mexico City, Mexico, 14000
Investigational Site Number 484004
Monterrey, Mexico, 64460
Investigational Site Number 484910
Morelia, Michoacan, Mexico, 58070
Investigational Site Number 484914
México Df, Mexico, 14080
Investigational Site Number 484020
Puebla, Mexico, 72460
Investigational Site Number 484017
Queretaro, Mexico, 76000
Investigational Site Number 484012
San Luis Potosi, Mexico, 72244
Investigational Site Number 484911
San Luis Potosi, Mexico, 78200
Investigational Site Number 484013
Xalapa, Mexico, 91020
Montenegro
Investigational Site Number 499501
Podgorica, Montenegro
Netherlands
Investigational Site Number 528003
Alkmaar, Netherlands, 1815 JD
Investigational Site Number 528005
Arnhem, Netherlands, 6815 AD
Investigational Site Number 528007
Leeuwarden, Netherlands, 8934 AD
Investigational Site Number 528004
Nieuwegein, Netherlands, 3435 CM
Investigational Site Number 528002
Rotterdam, Netherlands, 3079 DZ
New Zealand
Investigational Site Number 554004
Auckland, New Zealand
Investigational Site Number 554001
Hamilton, New Zealand, 3200
Investigational Site Number 554002
Nelson, New Zealand, 7040
Norway
Investigational Site Number 578903
Arendal, Norway, 4809
Investigational Site Number 578901
Bergen, Norway, 5021
Investigational Site Number 578902
Stavanger, Norway, 4011
Panama
Investigational Site Number 591504
Panama, Panama
Investigational Site Number 591502
Panamá, Panama
Peru
Investigational Site Number 604005
Lambayeque, Peru
Investigational Site Number 604006
Lima, Peru, LIMA 27
Investigational Site Number 604002
Lima, Peru, 051
Investigational Site Number 604008
Lima, Peru
Investigational Site Number 604003
Lima, Peru, LIMA 11
Investigational Site Number 604011
Lima, Peru, 051
Investigational Site Number 604012
Lima, Peru, LIMA 31
Investigational Site Number 604014
Lima, Peru, LIMA 01
Investigational Site Number 604017
Lima, Peru, LIMA 13
Poland
Investigational Site Number 616005
Bialystok, Poland, 15-276
Investigational Site Number 616038
Bialystok, Poland, 15-276
Investigational Site Number 616017
Bydgoszcz, Poland, 85-168
Investigational Site Number 616009
Bytom, Poland, 41-902
Investigational Site Number 616040
Elblag, Poland, 82-300
Investigational Site Number 616027
Elk, Poland, 19-300
Investigational Site Number 616023
Gdansk, Poland, 80-952
Investigational Site Number 616032
Jelenia Gora, Poland, 58-506
Investigational Site Number 616037
Katowice, Poland, 40-635
Investigational Site Number 616046
Katowice, Poland, 40-635
Investigational Site Number 616034
Klodzko, Poland, 57-300
Investigational Site Number 616002
Krakow, Poland, 31-501
Investigational Site Number 616045
Krakow, Poland, 31 -202
Investigational Site Number 616029
Lodz, Poland, 91-347
Investigational Site Number 616004
Lomza, Poland, 18-400
Investigational Site Number 616024
Lubin, Poland, 59-301
Investigational Site Number 616041
Lublin, Poland, 20-954
Investigational Site Number 616016
Ostroleka, Poland, 07-400
Investigational Site Number 616047
Radom, Poland, 26-610
Investigational Site Number 616003
Radom, Poland, 26-600
Investigational Site Number 616033
Rybnik, Poland, 44-200
Investigational Site Number 616019
Tarnów, Poland, 33-100
Investigational Site Number 616022
Torun, Poland, 87-100
Investigational Site Number 616018
Walbrzych, Poland, 58-309
Investigational Site Number 616001
Warszawa, Poland, 04-628
Investigational Site Number 616014
Warszawa, Poland, 02-507
Investigational Site Number 616031
Wloclawek, Poland, 87-800
Investigational Site Number 616015
Wroclaw, Poland, 50-420
Investigational Site Number 616020
Zamosc, Poland, 22-400
Portugal
Investigational Site Number 620010
Almada, Portugal, 2801-951
Investigational Site Number 620006
Amadora, Portugal, 2720
Investigational Site Number 620001
Coimbra, Portugal, 3000-075
Investigational Site Number 620002
Coimbra, Portugal, 3041-801
Investigational Site Number 620003
Lisboa, Portugal, 1169-024
Investigational Site Number 620015
Ponta Delgada, Portugal, 9500-370
Investigational Site Number 620004
Setúbal, Portugal, 2910-446
Investigational Site Number 620011
Évora, Portugal, 7000
Romania
Investigational Site Number 642002
Brasov, Romania, 500059
Investigational Site Number 642004
Bucuresti, Romania, 011461
Investigational Site Number 642001
Bucuresti, Romania, 014461
Investigational Site Number 642005
Cluj Napoca, Romania, 400001
Investigational Site Number 642003
Targu-Mures, Romania, 20475
Russian Federation
Investigational Site Number 643018
Barnaul, Russian Federation, 656055
Investigational Site Number 643015
Ekaterinburg, Russian Federation, 620109
Investigational Site Number 643011
Kemerovo, Russian Federation, 650002
Investigational Site Number 643014
Krasnodar, Russian Federation, 350086
Investigational Site Number 643021
Krasnoyarsk, Russian Federation, 660022
Investigational Site Number 643001
Moscow, Russian Federation, 121552
Investigational Site Number 643020
Moscow, Russian Federation, 115446
Investigational Site Number 643005
Moscow, Russian Federation, 105229
Investigational Site Number 643004
Moscow, Russian Federation, 111539
Investigational Site Number 643003
Moscow, Russian Federation, 121359
Investigational Site Number 643016
Nizniy Novgorod, Russian Federation, 603005
Investigational Site Number 643024
Novosibirsk, Russian Federation, 630055
Investigational Site Number 643008
Saint-Peterburg, Russian Federation, 196105
Investigational Site Number 643019
Saint-Petersburg, Russian Federation, 194156
Investigational Site Number 643013
Samara, Russian Federation, 443070
Investigational Site Number 643007
St-Petersburg, Russian Federation, 197341
Investigational Site Number 643006
St-Petersburg, Russian Federation, 192242
Investigational Site Number 643025
St-Petersburg, Russian Federation, 195067
Investigational Site Number 643012
Tomsk, Russian Federation, 634012
Investigational Site Number 643023
Volgograd, Russian Federation, 400008
Investigational Site Number 643017
Yaroslavl, Russian Federation, 150062
Serbia
Investigational Site Number 688505
Belgrade, Serbia, 11040
Investigational Site Number 688501
Kragujevac, Serbia, 34000
Investigational Site Number 688503
Nis, Serbia, 18000
Investigational Site Number 688502
Sremska Kamenica, Serbia, 21204
Investigational Site Number 688504
Zemun, Serbia, 11080
Investigational Site Number 688506
Zemun, Serbia, 11080
Singapore
Investigational Site Number 702001
Singapore, Singapore, 168752
Investigational Site Number 702002
Singapore, Singapore, 529889
Slovakia
Investigational Site Number 703003
Banska Bystrica, Slovakia, 97401
Investigational Site Number 703002
Martin, Slovakia, 03659
Investigational Site Number 703001
Nitra, Slovakia, 950 01
South Africa
Investigational Site Number 710004
Alberton, South Africa, 1450
Investigational Site Number 710001
Cape Town, South Africa, 7925
Investigational Site Number 710005
Cape Town, South Africa, 7500
Investigational Site Number 710003
Centurion, South Africa, 181
Investigational Site Number 710002
Kuils River, South Africa, 7580
Investigational Site Number 710007
Pretoria, South Africa
Spain
Investigational Site Number 724013
Alcorcón, Spain, 28992
Investigational Site Number 724001
Alicante, Spain, 03010
Investigational Site Number 724014
Badalona, Spain, 08916
Investigational Site Number 724901
Barcelona, Spain, 08907
Investigational Site Number 724021
Barcelona, Spain, 08025
Investigational Site Number 724025
Barcelona, Spain, 08035
Investigational Site Number 724002
Barcelona, Spain, 08036
Investigational Site Number 724022
Barcelona, Spain, 08003
Investigational Site Number 724007
Cáceres, Spain, 10003
Investigational Site Number 724026
Elche, Spain, 03293
Investigational Site Number 724016
Galdakao, Spain, 48960
Investigational Site Number 724023
Girona, Spain, 17007
Investigational Site Number 724006
La Laguna, Spain, 38320
Investigational Site Number 724027
Madrid, Spain, 28041
Investigational Site Number 724003
Madrid, Spain, 28035
Investigational Site Number 724902
Madrid, Spain, 28040
Investigational Site Number 724904
Murcia, Spain, 30120
Investigational Site Number 724017
Málaga, Spain, 29010
Investigational Site Number 724018
San Juan De Alicante, Spain, 03550
Investigational Site Number 724005
Santander, Spain, 39008
Investigational Site Number 724012
Santiago De Compostela, Spain, 15706
Investigational Site Number 724903
Terrassa, Spain, 08221
Investigational Site Number 724010
Torrevieja, Spain
Investigational Site Number 724024
Valencia, Spain, 46010
Switzerland
Investigational Site Number 756001
Lugano, Switzerland, 6900
Investigational Site Number 756002
Zürich, Switzerland, 8091
Taiwan
Investigational Site Number 158002
Kaohsiung, Taiwan, 833
Investigational Site Number 158007
Kaohsiung, Taiwan, 807
Investigational Site Number 158003
Linkou, Taiwan
Investigational Site Number 158008
Taichung, Taiwan, 40447
Investigational Site Number 158001
Taipei, Taiwan, 104
Investigational Site Number 158904
Taipei, Taiwan, 100
Investigational Site Number 158009
Taipei, Taiwan, 220
Thailand
Investigational Site Number 764901
Bangkok, Thailand, 10400
Investigational Site Number 764005
Bangkok, Thailand, 10700
Investigational Site Number 764002
Bangkok, Thailand, 10330
Investigational Site Number 764004
Khon Kaen, Thailand, 40002
Investigational Site Number 764007
Klong Luang, Thailand, 12120
Investigational Site Number 764903
Muang, Thailand, 50200
Investigational Site Number 764006
Rajathavee, Thailand, 10400
Tunisia
Investigational Site Number 788002
Ariana, Tunisia, 2080
Investigational Site Number 788005
Monastir, Tunisia, 5000
Investigational Site Number 788006
Monastir, Tunisia, 5000
Investigational Site Number 788004
Tunis, Tunisia, 1008
Investigational Site Number 788001
Tunis, Tunisia, 1008
Turkey
Investigational Site Number 792010
Adana, Turkey, 01339
Investigational Site Number 792023
Ankara, Turkey, 06100
Investigational Site Number 792009
Antalya, Turkey, 07059
Investigational Site Number 792008
Bursa, Turkey, 16100
Investigational Site Number 792022
Bursa, Turkey, 16509
Investigational Site Number 792030
Edirne, Turkey, 22030
Investigational Site Number 792006
Erzurum, Turkey, 25070
Investigational Site Number 792020
Eskisehir, Turkey, 26480
Investigational Site Number 792004
Gaziantep, Turkey, 27060
Investigational Site Number 792029
Istanbul, Turkey
Investigational Site Number 792032
Istanbul, Turkey, 34093
Investigational Site Number 792016
Istanbul, Turkey, 34846
Investigational Site Number 792028
Istanbul, Turkey, 34390
Investigational Site Number 792018
Istanbul, Turkey, 34034
Investigational Site Number 792001
Izmir, Turkey, 35340
Investigational Site Number 792011
Izmir, Turkey, 35100
Investigational Site Number 792003
Izmir, Turkey, 35360
Investigational Site Number 792012
Kayseri, Turkey, 38039
Investigational Site Number 792014
Kocaeli, Turkey, 41300
Investigational Site Number 792015
Konya, Turkey, 42080
Investigational Site Number 792025
Malatya, Turkey
Investigational Site Number 792019
Mersin, Turkey, 33169
Investigational Site Number 792021
Samsun, Turkey, 55200
Investigational Site Number 792026
Sivas, Turkey, 58140
Ukraine
Investigational Site Number 804004
Cherkasy, Ukraine, 18000
Investigational Site Number 804001
Kharkiv, Ukraine, 61018
Investigational Site Number 804005
Lviv, Ukraine, 79015
Investigational Site Number 804003
Zaporozhie, Ukraine, 69600
United Kingdom
Investigational Site Number 826008
Bournemouth, United Kingdom, BH7 7DW
Investigational Site Number 826007
Bradford, United Kingdom, BD9 6RJ
Investigational Site Number 826001
Craigavon, United Kingdom, BT63 5QQ
Investigational Site Number 826005
East Kilbride, United Kingdom, G75 8RG
Investigational Site Number 826002
Hull, United Kingdom, HU16 5JQ
Investigational Site Number 826006
Manchester, United Kingdom, M13 9WL
Investigational Site Number 826003
St Leonards, United Kingdom, TN37 7RD
Vietnam
Investigational Site Number 704006
Hanoi, Vietnam
Investigational Site Number 704004
Ho Chi Minh City, Vietnam
Investigational Site Number 704001
Ho Chi Minh City, Vietnam
Investigational Site Number 704003
Ho Chi Minh City, Vietnam
Investigational Site Number 704005
Ho Chi Minh City, Vietnam
Sponsors and Collaborators
Sanofi
Investigators
Study Director: Clinical Sciences & Operations Sanofi
  More Information

No publications provided by Sanofi

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT01076764     History of Changes
Other Study ID Numbers: EFC6204, 2009-016568-36
Study First Received: February 25, 2010
Last Updated: May 16, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Angina, Unstable
Infarction
Myocardial Infarction
Acute Coronary Syndrome
Angina Pectoris
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Chest Pain
Pain
Signs and Symptoms
Ischemia
Pathologic Processes
Necrosis
Calcium heparin
Heparin
Eptifibatide
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents
Platelet Aggregation Inhibitors

ClinicalTrials.gov processed this record on July 29, 2014